Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 3, 2026Breast Cancer Targets and TherapyOpen Access

Prognostic Value of Ki-67 and Progesterone Receptor for Risk Stratification and Outcomes by Adjuvant Chemotherapy in Early Luminal-Type Breast Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

HCHung-Hsun ChenSCShu-Jyuan ChangJKJung-Yu Kan

Discussion

Loading...

Member takes

Overview

This retrospective study assesses risk stratification and clinical outcomes in early luminal-type breast cancer based on Ki-67 and progesterone receptor levels.

Key Points

  • The aim is to develop a stratification framework and risk score to predict outcomes for hormone receptor-positive early breast cancer patients after chemotherapy.
  • Conducted a retrospective analysis of two cohorts totaling 3780 patients.
  • Categorized patients into four risk groups based on PR and Ki-67 levels.
  • Developed a quantitative risk score using clinical and pathological parameters.
  • Evaluated the impact of adjuvant chemotherapy on disease-free survival.
  • The PR10/Ki20 model showed consistent prognostic performance across both cohorts.
  • High-risk patients had poorer disease-free and overall survival compared to low-risk patients.
  • Adjuvant chemotherapy improved disease-free survival for high-risk patients but not for low-risk patients.
  • The quantitative risk score effectively differentiated between high- and low-risk groups based on survival outcomes.

Cite This Study

Chen et al. (2026) studied this question.

synapsesocial.com/papers/69cf59635a333a821460a119https://doi.org/10.2147/bctt.s597707
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The predictive role of Ki67 in pathological complete response (pCR) and invasive disease-free survival (IDFS) in HER2-positive breast cancer: a bi-centric retrospective cohort study of 244 cases.2026
  2. 2The predictive role of Ki67 in pathological complete response (pCR) and invasive disease-free survival (IDFS) in HER2-positive breast cancer: A retrospective study of 246 cases.2024
  3. 3The REMAR (Rhein-Main-Registry) real-world study: prospective evaluation of the 21-gene breast recurrence score® assay in addition to Ki-67 for adjuvant treatment decisions in early-stage breast cancer2024 · 6 citations
  4. 4A pathology-based surrogate model for chemotherapy decision-making in intermediate-risk luminal breast cancer: validation of histologic grade and Ki67 in a Chinese population2026
  5. 5156P The impact of Ki-67 on prognosis and chemotherapy benefit in breast cancer patients with ER-positive/HER2-negative micrometastatic disease in sentinel lymph nodes: A register-based cohort study2024 · 1 citations